Zoetis Quarterly Corporate Performance - Third Quarter 2026 - ZOETIS INC

Financial Performance:

• Third quarter 2026 revenue was $2.4 billion, representing a 1% decline on both reported and organic operational basis.
• Adjusted earnings per share (EPS) were $1.75, up 1% year-over-year, driven by share repurchases.
• Adjusted net income was $720 million, a 7% decline on an organic operational basis.
• Adjusted gross margin was 71%, down 30 basis points on a reported basis (down 60 basis points operationally) due to pricing initiatives, product mix, and inventory charges, partially offset by favorable foreign exchange (30 bps) and tariff refunds.
• Adjusted operating expenses were $749 million, flat operationally, with SG&A and R&D also flat despite increased digital investments offset by savings in incentive compensation.
• Companion animal revenue declined 5% globally ($1.6 billion), driven by an 8% drop in the U.S.; International companion animal revenue was flat ($1.1 billion).
• Livestock revenue grew 7% to $797 million, with U.S. up 5% and International up 9%.
• Companion animal diagnostics revenue grew 13% to $122 million, driven by acquisitions (VitalRads, VPG) and underlying platform adoption.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance narrowed to $9.22–$9.32 billion (organic operational decline of 1–2%).
• Full-year adjusted net income guidance raised to $2.60–$2.64 billion (organic operational decline of 5–7%).
• Full-year adjusted diluted EPS guidance raised to $6.25–$6.35.
• No specific 2027 guidance provided; management expects a prudent approach, not assuming macro improvements or competitive normalization in 2027.
• 2027 revenue is expected to reflect continued promotional headwinds and limited contribution from new major launches, with impact building in late 2027 and accelerating in 2028.
• Long-term goal to deliver one significant major market approval annually, with 2026 milestones met or exceeded.

Business Segments and Product Lines:

• Dermatology: Global sales down 16% ($396M); U.S. down 13% ($266M) due to Apoquel share loss and generic pressure; International down 20% ($130M) due to European competition. Mitigated by slowing share loss (from -7 pts to -4 pts) via gross-to-net promotions.
• Parasiticides (Simparica): Global growth of 1% ($358M); U.S. down 2% due to clinic visit declines; International up 10% driven by Simparica Trio momentum.
• OA Pain: Global sales up 2% ($137M); U.S. down 12%; International up 13% driven by Lanivia and Portela launches in EU/Canada.
• Livestock: Strong growth led by cattle, swine, and poultry vaccines; U.S. supply of Septa IV stable.
• Innovation Pipeline: Upcoming Q4 approval for long-acting Cytopoint; Year-end approval for Simparica Duo (Rx only); U.S. approval expected for Lanivia in 2027.
• Diagnostics: Double-digit growth driven by point-of-care and imaging platforms; new analyzer OmniMax in development.

Market and Competitive Landscape:

• Companion Animals: Facing headwinds from rising vet costs (up 50% since 2022), softer consumer confidence, and a shift from dogs to cats (reducing medicalized service demand). U.S. vet visits down 3% YTD.
• Competition: Intense pressure in dermatology (Apoquel, Cytopoint) and parasiticides (generic competition for Convenia, Serenia, and new entrants). Retail channel growth slowing, while home delivery remains strong.
• Livestock: Benefiting from global demand for quality protein, food security initiatives, and a "One Health" approach. Market remains cyclical, influenced by disease, weather, and production cycles.
• Geography: Developed markets face pet care affordability issues; emerging markets expected to drive long-term growth with lower penetration rates.

Risks and Challenges:

• Affordability: Pet owners delaying or altering care due to high costs; 37% cite ownership cost as a concern.
• Competition: New product launches and generic entries eroding market share in key franchises (Dermatology, Parasiticides) faster than historically expected.
• Market Dynamics: Declining dog ownership and clinic visits in developed markets; potential supply constraints for new entrants could shift if they expand.
• Regulatory/Supply: Dependence on timely regulatory approvals for pipeline products; weather and disease outbreaks impacting livestock results.

Management Commentary and Tone:

• Tone was disciplined, transparent, and focused on defensive execution while maintaining innovation investment.
• New COO Jay Saccaro emphasized a world-class portfolio, pipeline catalysts, and a focus on cost competitiveness and efficiency.
• CEO Kristen Peck highlighted the diversification strategy, noting that livestock and diagnostics are offsetting companion animal weakness.
• Management acknowledged the need for sustained gross-to-net promotional investment to defend share until market stabilization is observed (targeting 12–18 months).
• Commitment to capital allocation: R&D investment remains priority, with excess capital returned to shareholders via dividends and buybacks ($2.4B in 2026 Q1–Q3).

Analyst Questions and Answers:

• Promotional Impact: Promotions slowed U.S. dermatology share loss to 4 points in Q3 (vs. 7 in Q2); Simparica Trio held 22.5% market share in the U.S.
• 2027 Outlook: Management is conservative on 2027, not assuming macro shifts; Q4 is expected to decelerate further (high single-digit decline vs. Q3) due to seasonality and Q3 promotional ramp.
• Dermatology Mix: Revenue decline driven primarily by volume loss; pricing impact was entirely gross-to-net investments, not list price changes.
• Simparica Duo: Approved for year-end; RX product addressing markets with high flea/tick but low heartworm risk; launch in 2027.
• International Performance: Flat international companion animal revenue masked strong growth in parasiticides and weakness in European dermatology.
• Cannibalization: OA pain growth in international markets (13%) confirms that new products (Lanivia/Portela) are expanding the total market despite some internal cannibalization.
• Margin Outlook: Full-year margin expected to be in line or better than guidance; future margin focus on manufacturing efficiency and SG&A savings to offset promotional spend.

Other Key Points:

• A $78 million non-GAAP impairment charge was recorded for in-process R&D assets due to updated development assumptions.
• New "Medical Hub" launched to provide veterinarians with scientific evidence and educational materials to support treatment decisions.
• Strategic focus on "growth to net" investments rather than "lift" to ensure clear ROI on promotional spend.
• Retail channel strategy includes auto-ship programs and targeted pricing to maintain compliance and share.
• Upcoming updates on the innovation pipeline (CKD, oncology, obesity, etc.) planned for the J.P. Morgan conference.